Display Devices for Diagnostic Radiology; Guidance for Industry and Food and Drug Administration Staff; Availability, 45853-45854 [2017-21078]
Download as PDF
Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
pursuant to Executive Order 13708, and
will expire on September 30, 2017.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class. SPR
was established to aid the Advisory
Board in carrying out its duty to advise
the Secretary, HHS, on dose
reconstruction. SPR is responsible for
overseeing, tracking, and participating
in the reviews of all procedures used in
the dose reconstruction process by the
NIOSH Division of Compensation
Analysis and Support (DCAS) and its
dose reconstruction contractor (Oak
Ridge Associated Universities—ORAU).
Matters to be Considered: The agenda
will include discussions on the
following dose reconstruction
procedures: DCAS Program Evaluation
Report 59 (addressing dose
reconstructions at the Norton Company,
Worcester MA); DCAS Report 5:
Alternative Dissolution Models for
Insoluble Plutonium 238; Outstanding
Findings of Prior Subcommittee
Reviews; and DCAS Procedures Not Yet
Reviewed. Agenda items are subject to
change as priorities dictate.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–21046 Filed 9–29–17; 8:45 am]
BILLING CODE 4163–19–P
VerDate Sep<11>2014
19:01 Sep 29, 2017
Jkt 244001
45853
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Food and Drug Administration
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–D–5140 for ‘‘Display Devices for
Diagnostic Radiology’’ comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
[Docket No. FDA–2017–D–5140]
Display Devices for Diagnostic
Radiology; Guidance for Industry and
Food and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the
guidance entitled ‘‘Display Devices for
Diagnostic Radiology.’’ This guidance
document provides recommendations
for the types of information you should
provide in your premarket notification
submission (510(k)) for display devices
intended for diagnostic radiology with
the assigned product code PGY. This
guidance replaces a previously issued
final guidance entitled ‘‘Display
Accessories for Full-Field Digital
Mammography Systems-Premarket
Notification (510(k)) Submissions’’
issued on May 30, 2008.
DATES: The announcement of the
guidance is published in the Federal
Register on October 2, 2017.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
E:\FR\FM\02OCN1.SGM
02OCN1
45854
Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance
document is available for download
from the internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Display Devices for
Diagnostic Radiology’’ to the Office of
the Center Director, Guidance and
Policy Development, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
FOR FURTHER INFORMATION CONTACT:
Robert Ochs, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4308, Silver Spring,
MD 20993–0002, 301–796–6661.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
I. Background
This guidance applies to display
devices intended for diagnostic
radiology as identified in Section III of
the guidance and currently classified
under 21 CFR 892.2050 as class II
devices according to section 513(a)(1) of
the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C.
360c(a)(1)) with the assigned product
code PGY. This guidance is intended to
assist industry in preparing a 510(k) for
display devices intended for use in
diagnostic radiology. This guidance
provides recommendations for the types
of information you should provide in
your 510(k) submission for display
devices intended for diagnostic
radiology. This information
supplements the requirements for a
510(k) submission found in 21 CFR 807
Subpart E, as well as recommendations
provided in other FDA guidance
documents concerning the specific
content of a 510(k) submission.
FDA considered comments on the
draft guidance that appeared in the
Federal Register of February 9, 2016 (81
FR 6869). FDA revised the guidance as
appropriate in response to the
comments.
This guidance applies to workstation
medical image displays for diagnostic
VerDate Sep<11>2014
19:01 Sep 29, 2017
Jkt 244001
radiology. These devices are classified
as class II devices that are intended to
be used in controlled viewing
conditions to display and view digital
images for primary image interpretation.
Display devices for diagnostic radiology
may also be referred to as soft-copy
displays or medical grade monitors.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
This guidance represents the current
thinking of FDA on Display Devices for
Diagnostic Radiology. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations. This
guidance is not subject to Executive
Order 12866.
Dated: September 25, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–21078 Filed 9–29–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–D–5372]
Marketing Clearance of Diagnostic
Ultrasound Systems and Transducers;
Draft Guidance for Industry and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Display Devices for Diagnostic
Radiology’’ may send an email request
to CDRH-Guidance@fda.hhs.gov to
receive an electronic copy of the
document. Please use the document
number 1500022 to identify the
guidance you are requesting.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the draft
guidance entitled ‘‘Marketing Clearance
of Diagnostic Ultrasound Systems and
Transducers; Draft Guidance for
Industry and Food and Drug
Administration Staff.’’ This draft
guidance provides detailed information
recommended for manufacturers
seeking marketing clearance of
diagnostic ultrasound systems and
transducers. This draft guidance is not
final nor is it in effect at this time.
DATES: Submit either electronic or
written comments on the draft guidance
by January 2, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
IV. Paperwork Reduction Act of 1995
Electronic Submissions
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 807, subpart E have been
approved under OMB control number
0910–0120; the collections of
information in 21 CFR part 801 have
been approved under OMB control
number 0910–0485; and the collections
of information in the guidance entitled
‘‘Requests for Feedback on Medical
Device Submissions: The PreSubmission Program and Meetings with
Food and Drug Administration Staff’’
have been approved under OMB control
number 0910–0756.
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
III. Electronic Access
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
SUMMARY:
E:\FR\FM\02OCN1.SGM
02OCN1
Agencies
[Federal Register Volume 82, Number 189 (Monday, October 2, 2017)]
[Notices]
[Pages 45853-45854]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-21078]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-D-5140]
Display Devices for Diagnostic Radiology; Guidance for Industry
and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the guidance entitled ``Display Devices for
Diagnostic Radiology.'' This guidance document provides recommendations
for the types of information you should provide in your premarket
notification submission (510(k)) for display devices intended for
diagnostic radiology with the assigned product code PGY. This guidance
replaces a previously issued final guidance entitled ``Display
Accessories for Full-Field Digital Mammography Systems-Premarket
Notification (510(k)) Submissions'' issued on May 30, 2008.
DATES: The announcement of the guidance is published in the Federal
Register on October 2, 2017.
ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-D-5140 for ``Display Devices for Diagnostic Radiology''
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://
[[Page 45854]]
www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Display Devices for Diagnostic Radiology'' to the Office of the
Center Director, Guidance and Policy Development, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your request.
FOR FURTHER INFORMATION CONTACT: Robert Ochs, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4308, Silver Spring, MD 20993-0002, 301-796-6661.
SUPPLEMENTARY INFORMATION:
I. Background
This guidance applies to display devices intended for diagnostic
radiology as identified in Section III of the guidance and currently
classified under 21 CFR 892.2050 as class II devices according to
section 513(a)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) (21 U.S.C. 360c(a)(1)) with the assigned product code PGY. This
guidance is intended to assist industry in preparing a 510(k) for
display devices intended for use in diagnostic radiology. This guidance
provides recommendations for the types of information you should
provide in your 510(k) submission for display devices intended for
diagnostic radiology. This information supplements the requirements for
a 510(k) submission found in 21 CFR 807 Subpart E, as well as
recommendations provided in other FDA guidance documents concerning the
specific content of a 510(k) submission.
FDA considered comments on the draft guidance that appeared in the
Federal Register of February 9, 2016 (81 FR 6869). FDA revised the
guidance as appropriate in response to the comments.
This guidance applies to workstation medical image displays for
diagnostic radiology. These devices are classified as class II devices
that are intended to be used in controlled viewing conditions to
display and view digital images for primary image interpretation.
Display devices for diagnostic radiology may also be referred to as
soft-copy displays or medical grade monitors.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). This guidance represents the
current thinking of FDA on Display Devices for Diagnostic Radiology. It
does not establish any rights for any person and is not binding on FDA
or the public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations. This guidance
is not subject to Executive Order 12866.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the Internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov. Persons
unable to download an electronic copy of ``Display Devices for
Diagnostic Radiology'' may send an email request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of the document.
Please use the document number 1500022 to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 807, subpart E have been
approved under OMB control number 0910-0120; the collections of
information in 21 CFR part 801 have been approved under OMB control
number 0910-0485; and the collections of information in the guidance
entitled ``Requests for Feedback on Medical Device Submissions: The
Pre-Submission Program and Meetings with Food and Drug Administration
Staff'' have been approved under OMB control number 0910-0756.
Dated: September 25, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-21078 Filed 9-29-17; 8:45 am]
BILLING CODE 4164-01-P